Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2001 Jun 7;344(23):1735-42.
doi: 10.1056/NEJM200106073442301.

Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A

D A Roth  1 , N E Tawa Jr, J M O'Brien, D A Treco, R F Selden; Factor VIII Transkaryotic Therapy Study Group
Affiliations
Free article
Clinical Trial

Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A

D A Roth et al. N Engl J Med. .
Free article

Abstract

Background: We tested the safety of a nonviral somatic-cell gene-therapy system in patients with severe hemophilia A.

Methods: An open-label, phase 1 trial was conducted in six patients with severe hemophilia A. Dermal fibroblasts obtained from each patient by skin biopsy were grown in culture and transfected with a plasmid containing sequences of the gene that encodes factor VIII. Cells that produced factor VIII were selected, cloned, and propagated in vitro. The cloned cells were then harvested and administered to the patients by laparoscopic injection into the omentum. The patients were followed for 12 months after the implantation of the genetically altered cells. An interim analysis was performed.

Results: There were no serious adverse events related to the use of factor VIII-producing fibroblasts or the implantation procedure. No long-term complications developed, and no inhibitors of factor VIII were detected. In four of the six patients, plasma levels of factor VIII activity rose above the levels observed before the procedure. The increase in factor VIII activity coincided with a decrease in bleeding, a reduction in the use of exogenous factor VIII, or both. In the patient with the highest level of factor VIII activity, the clinical changes lasted approximately 10 months.

Conclusions: Implantation of genetically altered fibroblasts that produce factor VIII is safe and well tolerated. This form of gene therapy is feasible in patients with severe hemophilia A.

PubMed Disclaimer

Comment in

  • Gene therapy for hemophilia.
    Miller DG, Stamatoyannopoulos G. Miller DG, et al. N Engl J Med. 2001 Jun 7;344(23):1782-4. doi: 10.1056/NEJM200106073442309. N Engl J Med. 2001. PMID: 11396447 No abstract available.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

LinkOut - more resources

  NODES
admin 1
twitter 2